Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of “Moderate Buy” by Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned an average rating of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $88.8571.

Several equities analysts have recently issued reports on LNTH shares. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research report on Friday. Wall Street Zen upgraded Lantheus from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 28th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Finally, JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th.

Institutional Investors Weigh In On Lantheus

Hedge funds have recently modified their holdings of the business. Stanley Laman Group Ltd. raised its position in shares of Lantheus by 38.7% during the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock worth $4,087,000 after purchasing an additional 22,229 shares during the period. Quantbot Technologies LP bought a new stake in shares of Lantheus during the third quarter worth $1,847,000. American Assets Inc. bought a new stake in shares of Lantheus during the third quarter worth $872,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Lantheus during the third quarter worth $2,184,000. Finally, Assetmark Inc. increased its position in shares of Lantheus by 20.1% during the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after acquiring an additional 19,844 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $85.50 on Monday. The firm has a fifty day moving average of $78.85 and a two-hundred day moving average of $68.21. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of 25.37 and a beta of -0.08. Lantheus has a 52 week low of $47.25 and a 52 week high of $108.91. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts predict that Lantheus will post 4.29 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.